文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

MULTIPAP Plus干预对共病与多重用药的年轻老年人改善初级保健处方实践的有效性:整群随机试验研究方案

Effectiveness of the MULTIPAP Plus intervention in youngest-old patients with multimorbidity and polypharmacy aimed at improving prescribing practices in primary care: study protocol of a cluster randomized trial.
PubMed 文献 · Trials · 2022-06-09

本研究为实用整群随机临床试验,在西班牙国家卫生系统卫生中心开展,随访18个月,以家庭医生为随机化单位、患者为分析单位。纳入65-74岁、患≥3种慢性病且近3个月用药≥5种的患者,样本量1148例(每臂574例)。评估基于ARIADNE原则的复杂干预MULTIPAP Plus相比常规照护在改善处方及成本效果方面的作用。

要点

  • MULTIPAP Plus为基于ARIADNE原则的复杂干预,含家庭医生培训、医患访谈和决策支持系统三部分。
  • 主要结局为观察期间住院或死亡的复合终点,以二分类变量衡量。
  • 样本量1148例(每臂574例),随访18个月,按意向性治疗原则分析。

核心结论

  • 旨在评估MULTIPAP Plus相比常规照护改善65-74岁共病与多重用药患者处方的有效性及成本效果。

研究设计与样本

  • 实用整群随机临床试验,随访18个月,在西班牙国家卫生系统卫生中心开展。
  • 随机化单位为家庭医生,分析单位为患者。
  • 纳入65-74岁、患≥3种慢性病且近3个月用药≥5种的患者,样本量1148例(每臂574例)。
  • 干预为基于ARIADNE原则的复杂干预,含家庭医生培训、医患访谈和决策支持系统三部分。

主要发现

  • 主要结局为观察期间住院或死亡的复合终点,以二分类变量衡量。
  • 次要结局包括住院次数、全因死亡率、卫生服务利用、生活质量(EQ-5D-5L)、功能(WHODAS)、跌倒、髋部骨折、处方及治疗依从性。
  • 主要结果为18个月时复合终点变量百分比的差异及其对应的95%CI,采用多水平分析调整主要混杂与预后因素,按意向性治疗原则分析。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The progressive ageing of the population is leading to an increase in multimorbidity and polypharmacy, which in turn may increase the risk of hospitalization and mortality. The enhancement of care with information and communications technology (ICT) can facilitate the use of prescription evaluation tools and support system for decision-making (DSS) with the potential of optimizing the healthcare delivery process. OBJECTIVE: To assess the effectiveness and cost-effectiveness of the complex intervention MULTIPAP Plus, compared to usual care, in improving prescriptions for young-old patients (65-74 years old) with multimorbidity and polypharmacy in primary care. METHODS/DESIGN: This is a pragmatic cluster-randomized clinical trial with a follow-up of 18 months in health centres of the Spanish National Health System. Unit of randomization: family physician. Unit of analysis: patient. POPULATION: Patients aged 65-74 years with multimorbidity (≥ 3 chronic diseases) and polypharmacy (≥ 5 drugs) during the previous 3 months were included. SAMPLE SIZE: n = 1148 patients (574 per study arm). INTERVENTION: Complex intervention based on the ARIADNE principles with three components: (1) family physician (FP) training, (2) FP-patient interview, and (3) decision-making support system. OUTCOMES: The primary outcome is a composite endpoint of hospital admission or death during the observation period measured as a binary outcome, and the secondary outcomes are number of hospital admission, all-cause mortality, use of health services, quality of life (EQ-5D-5L), functionality (WHODAS), falls, hip fractures, prescriptions and adherence to treatment. Clinical and sociodemographic factors will be explanatory variables. STATISTICAL ANALYSIS: The main result is the difference in percentages in the final composite endpoint variable at 18 months, with its corresponding 95% CI. Adjustments by the main confounding and prognostic factors will be performed through a multilevel analysis. All analyses will be carried out in accordance to the intention-to-treat principle. DISCUSSION: It is important to prevent the cascade of negative health and health care impacts attributable to the multimorbidity-polypharmacy binomial. ICT-enhanced routine clinical practice could improve the prescription process in patient care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04147130 . Registered on 22 October 2019.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Del Cura-González I, López-Rodríguez JA, Leiva-Fernández F, et al. Effectiveness of the MULTIPAP Plus intervention in youngest-old patients with multimorbidity and polypharmacy aimed at improving prescribing practices in primary care: study protocol of a cluster randomized trial. Trials. 2022. PMID: 35681224. doi:10.1186/s13063-022-06293-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。